Sanofi acquires Tidal Therapeutics, expands vaccine manufacturing

By The Science Advisory Board staff writers

April 12, 2021 -- Sanofi announced that it has purchased Tidal Therapeutics for $160 million and plans to expand its vaccine manufacturing capability through a site in Singapore.

Tidal Therapeutics is a private, preclinical stage biotechnology company. Its acquisition adds in vivo immune cell reprogramming and messenger RNA (mRNA) research technology to Sanofi's portfolio, the company said. In addition to the initial payment, Sanofi will pay Tidal up to $310 million as it achieves particular milestones.

Sanofi also announced that it is investing 400 million euros ($477 million U.S.) in a production site in Singapore to expand its vaccine manufacturing capability. The facility will contain a central unit that houses several fully digitalized modules that allow production of three to four vaccines simultaneously. The modular, flexible design will be able to leverage multiple vaccine manufacturing technology platforms based on different cell types. The carbon-neutral site is entering its design phase, and construction is expected to begin in the third quarter of 2021. It should be fully operational in 2026, Sanofi said.

Sanofi to build new manufacturing facility in Toronto
Sanofi announced an investment of approximately $737 million U.S. in a new vaccine manufacturing facility at its existing site in Toronto, Canada,...
GVN adds Sanofi Pasteur as partner against viral threats
The Global Virus Network (GVN) has added Sanofi Pasteur, the vaccines business unit of Sanofi, as a member of the GVN Healthcare & Pharma Centers of Excellence...
Sanofi, Translate Bio begin early-stage trials of mRNA COVID-19 vaccine
Sanofi Pasteur, the vaccine unit of Sanofi, is partnering with Translate Bio on a phase I/II clinical trial for MRT5500, a messenger RNA (mRNA) vaccine...
Sirion Biotech, Sanofi to improve AAV capsids
Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors...
Sanofi, GSK start phase II COVID-19 vaccine study
Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter